FAPI PET/CT在胰腺癌诊治中的研究与展望

Research and prospect of FAPI PET/CT in diagnosis and treatment of pancreatic cancers

胰腺癌是一种病死率极高的恶性肿瘤,且早期诊断困难,其有效治疗依旧是临床面临的一大难题。近年来,放射性核素标记的成纤维细胞活化蛋白抑制剂(FAPI)分子探针已成为胰腺癌诊治研究的热点。其在胰腺癌细胞中的摄取明显高于正常组织细胞,具有良好的靶本比,有利于对胰腺癌原发灶及其转移灶进行准确地显像诊断,为后续治疗方案的制定提供更多信息。同时,相关放射性核素标记的FAPI也给胰腺癌治疗带来了新的思路。笔者就FAPI在胰腺癌诊治中的研究进展进行综述,以期推动核医学在胰腺癌诊治中的应用。

Pancreatic cancer is a highly lethal malignant tumor that is difficult to diagnose in its early stages,and its effective treatment remains a significant challenge in clinical practice.Recently,radiolabeled fibroblast activation protein inhibitor(FAPI)as molecular probes have emerged as a focal point in pancreatic cancer diagnosis and treatment research.Its uptake in pancreatic cancer cells is significantly higher than in normal tissue cells,exhibiting an excellent tumor-to-background ratio,which facilitates accurate imaging and diagnosis of both primary and metastatic pancreatic cancer lesions,thereby providing more information for the formulation of subsequent treatment plans.Additionally,radiolabeled FAPI has pioneered novel approaches in the treatment of pancreatic cancer.Here,the author reviews the research progress of FAPI in the diagnosis and treatment of pancreatic cancer,with the aim of promoting the application of nuclear medicine in the diagnosis and treatment of pancreatic cancer.